BioLum Sciences

Executive Summary

BioLum Sciences is a San Diego-based pre-clinical diagnostics company leveraging a proprietary chemiluminescence platform to detect reactive oxygen, nitrogen, and sulfur species (RONSS). The technology aims to accelerate drug discovery and enable early disease detection through customized bioanalytical services and future diagnostic kits, with a long-term goal of point-of-care testing. The company's approach offers superior sensitivity and specificity compared to conventional methods, positioning it as a potential enabler in the oxidative stress biomarker space. While still in early stages, BioLum Sciences has the opportunity to disrupt both pharmaceutical R&D and clinical diagnostics if it can successfully validate its platform and achieve regulatory milestones. However, as a private, pre-revenue entity with limited disclosed funding, execution risk remains high. The company's focus on a niche but growing area of biomarker detection, combined with increasing interest in precision medicine, suggests significant upside if technological and commercial hurdles are overcome.

Upcoming Catalysts (preview)

• Q4 2026Completion of key validation study for RONSS detection platform70% success
• Q2 2027Partnership with major pharmaceutical company for drug discovery services50% success
• Q1 2027Series A funding round to support clinical kit development60% success